CTOR
Income statement / Annual
Last year (2025), Citius Oncology Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Citius Oncology Inc.'s net income was -$24.76 M.
See Citius Oncology Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$6.42 M
|
$4.93 M
|
$4.24 M
|
$6.86 M
|
| General & Administrative Expenses |
$17.10 M
|
$15.65 M
|
$7.88 M
|
$2.86 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.10 M
|
$15.65 M
|
$7.88 M
|
$2.86 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$23.52 M
|
$20.57 M
|
$12.12 M
|
$9.71 M
|
| Cost And Expenses |
$23.52 M
|
$20.57 M
|
$12.12 M
|
$9.71 M
|
| Interest Income |
$36.37 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$218.03 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$9.71 M
|
| EBITDA |
-$23.49 M |
-$20.57 M |
-$12.12 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$181.66 K
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$23.70 M
|
-$20.57 M
|
-$12.12 M
|
-$9.71 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.06 M
|
$576.00 K
|
$576.00 K
|
$1.15 M
|
| Net Income |
-$24.76 M
|
-$21.15 M
|
-$12.70 M
|
-$10.87 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.34 |
-0.3 |
-0.19 |
-0.0763 |
| EPS Diluted |
-0.34 |
-0.3 |
-0.19 |
-0.0763 |
| Weighted Average Shares Out |
$73.27 M
|
$71.55 M
|
$89.48 M
|
$90.16 M
|
| Weighted Average Shares Out Diluted |
$73.27 M
|
$71.55 M
|
$89.48 M
|
$90.16 M
|
| Link |
|
|
|
|
